Evidence map›Paper›PMID 37209218›Full record

ArticleCancer immunology, immunotherapy : CII2023

Sequential CAR T cell and targeted alpha immunotherapy in disseminated multiple myeloma.

Dennis Awuah, Megan Minnix, Enrico Caserta, Theophilus Tandoh, Vikram Adhikarla, Erasmus Poku, Russell Rockne, Flavia Pichiorri, John E Shively, Xiuli Wang

Open access · hybridAbstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Cancer immunology, immunotherapy : CII, 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 5 papers.

0numbers the graph read from it
0cells of the map it votes in
5citing papers in PubMed
1.8field-weighted citation impact, top 13% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

5 citing papers in PubMed, 8 citations in OpenAlex.

  1. Review
  2. Review
  3. Review
  4. Article
  5. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

10 authors at 3 institutions in 1 country.

Dennis Awuah *Department of Hematology, City of Hope Medical Center, Beckman Research Institute, Duarte, CA, 91010, USA.
Megan Minnix *Department of Immunology and Theranostics, Beckman Research Institute, City of Hope, Duarte, CA, 91010, USA.
Enrico Caserta *Department of Hematologic Malignancies Research Institute, City of Hope Medical Center, Duarte, CA, 91010, USA.
Theophilus TandohDepartment of Hematologic Malignancies Research Institute, City of Hope Medical Center, Duarte, CA, 91010, USA.
Vikram AdhikarlaDivision of Mathematical Oncology and Computational Systems Biology, Beckman Research Institute, City of Hope, Duarte, CA, 91010, USA.
Erasmus PokuCity of Hope Medical Center, Duarte, CA, 91010, USA.
Russell RockneDivision of Mathematical Oncology and Computational Systems Biology, Beckman Research Institute, City of Hope, Duarte, CA, 91010, USA.
Flavia PichiorriDepartment of Hematologic Malignancies Research Institute, City of Hope Medical Center, Duarte, CA, 91010, USA. fpichiorri@coh.org.
John E ShivelyDepartment of Immunology and Theranostics, Beckman Research Institute, City of Hope, Duarte, CA, 91010, USA. Jshively@coh.org.
Xiuli WangDepartment of Hematology, City of Hope Medical Center, Beckman Research Institute, Duarte, CA, 91010, USA. xiuwang@coh.org.
City of Hope · USCity Of Hope National Medical Center · USBeckman Research Institute

Funding

Transgenic Mouse FacilityP30CA033572 · NCI · CITY OF HOPE/BECKMAN RESEARCH INSTITUTE · PI XIWEI WU · 1985 to 2026
$86.3M
Exploring the preclinical relevance of therapeutic radiolabeled daratumumab (anti-CD38) in combination with anti-CS1 CAR T cells as a novel combinatorial treatment for multiple myelomaR01CA238429 · NCI · BECKMAN RESEARCH INSTITUTE/CITY OF HOPE · PI PICHIORRI, FLAVIA, ROCKNE, RUSSELL CHRISTIAN · 2019 to 2023
$2.0M
Improving Outcomes for Multiple Myeloma Patients through Novel Therapeutic InterventionsR50CA252135 · NCI · BECKMAN RESEARCH INSTITUTE/CITY OF HOPE · PI CASERTA, ENRICO · 2021 to 2025
$564k
NCI NIH HHS P30 CA033572NCI NIH HHS R01 CA238429NCI NIH HHS R50 CA252135
6 · The paper itself

Abstract

Multiple myeloma (MM) is still an incurable disorder despite improved antibody and cellular therapies against different MM antigens. Single targeted antigens have so far been ineffective against MM with most patients relapsing after initial response. Hence, sequential immunotherapies directed at different targets are expected to perform better than monotherapy alone. Here, we optimized and established in preclinical studies the therapeutic rationale of using targeted alpha therapy (TAT) directed against CD38 antigen (

Indexed as

Multiple MyelomaReceptors, Chimeric AntigenB-Cell Maturation AntigenHumansImmunotherapyImmunotherapy, AdoptiveNeoplasm Recurrence, LocalT-LymphocytesB-Cell Maturation AntigenReceptors, Chimeric AntigenCAR T therapyMultiple myelomaTargeted alpha therapy

Identifiers

PMID37209218
PMCPMC10361855
OpenAlexW4377136984

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.